CU Medical Systems, Inc. (KOSDAQ:115480)
South Korea · Delayed Price · Currency is KRW 571.00
-6.00 (-1.04%)
At close: Apr 17, 2026
CU Medical Systems Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 48,223 | 40,629 | 41,803 | 46,957 | 35,402 |
Other Revenue | - | - | -0 | -0 | - |
| 48,223 | 40,629 | 41,803 | 46,957 | 35,402 | |
Revenue Growth (YoY) | 18.69% | -2.81% | -10.98% | 32.64% | 25.01% |
Cost of Revenue | 19,785 | 19,169 | 21,479 | 22,309 | 16,980 |
Gross Profit | 28,438 | 21,460 | 20,324 | 24,648 | 18,422 |
Selling, General & Admin | 12,040 | 10,029 | 9,186 | 9,312 | 8,072 |
Research & Development | 2,465 | 2,186 | 2,912 | 2,623 | 1,845 |
Amortization of Goodwill & Intangibles | 438.05 | 422 | 414.33 | 408.03 | 892.08 |
Other Operating Expenses | 258.92 | 182.92 | 108.32 | 212.62 | 100.13 |
Operating Expenses | 17,365 | 14,106 | 15,264 | 13,366 | 16,047 |
Operating Income | 11,073 | 7,354 | 5,060 | 11,282 | 2,376 |
Interest Expense | -1,446 | -1,147 | -325.57 | -454.24 | -1,136 |
Interest & Investment Income | 523.13 | 260.31 | 89.71 | 98.72 | 162.01 |
Earnings From Equity Investments | - | - | 105.46 | - | 52.92 |
Currency Exchange Gain (Loss) | -525.16 | 685.08 | -107.07 | 311.12 | 363.39 |
Other Non Operating Income (Expenses) | 465.6 | -720.52 | 137.38 | -347.03 | -4,082 |
EBT Excluding Unusual Items | 10,090 | 6,433 | 4,960 | 10,891 | -2,264 |
Gain (Loss) on Sale of Investments | -8,585 | -9,214 | -9,637 | -1,024 | -8,046 |
Gain (Loss) on Sale of Assets | 3.5 | -42.8 | 14.42 | 861.77 | -63.41 |
Asset Writedown | - | -1,004 | -2,781 | -370.57 | -5,267 |
Other Unusual Items | - | 1,353 | - | 87.97 | 499.72 |
Pretax Income | 1,509 | -2,474 | -7,443 | 10,446 | -15,140 |
Income Tax Expense | 689.77 | 666.52 | 692.81 | 934.62 | -999.21 |
Earnings From Continuing Operations | 819.2 | -3,141 | -8,136 | 9,511 | -14,141 |
Net Income to Company | 819.2 | -3,141 | -8,136 | 9,511 | -14,141 |
Minority Interest in Earnings | - | -63.65 | -67.68 | -85.88 | 160.15 |
Net Income | 819.2 | -3,204 | -8,204 | 9,425 | -13,981 |
Net Income to Common | 819.2 | -3,204 | -8,204 | 9,425 | -13,981 |
Shares Outstanding (Basic) | 59 | 51 | 48 | 45 | 34 |
Shares Outstanding (Diluted) | 59 | 51 | 48 | 45 | 34 |
Shares Change (YoY) | 15.04% | 6.39% | 5.90% | 33.07% | 52.90% |
EPS (Basic) | 14.00 | -63.00 | -171.59 | 208.78 | -412.11 |
EPS (Diluted) | 14.00 | -63.00 | -172.00 | 208.78 | -412.11 |
Free Cash Flow | 8,629 | -5,984 | 1,893 | -8,465 | -4,696 |
Free Cash Flow Per Share | 147.47 | -117.65 | 39.59 | -187.50 | -138.42 |
Gross Margin | 58.97% | 52.82% | 48.62% | 52.49% | 52.04% |
Operating Margin | 22.96% | 18.10% | 12.11% | 24.03% | 6.71% |
Profit Margin | 1.70% | -7.89% | -19.63% | 20.07% | -39.49% |
Free Cash Flow Margin | 17.89% | -14.73% | 4.53% | -18.03% | -13.26% |
EBITDA | 14,366 | 10,013 | 6,995 | 12,933 | 4,320 |
EBITDA Margin | 29.79% | 24.64% | 16.73% | 27.54% | 12.20% |
D&A For EBITDA | 3,293 | 2,658 | 1,935 | 1,651 | 1,945 |
EBIT | 11,073 | 7,354 | 5,060 | 11,282 | 2,376 |
EBIT Margin | 22.96% | 18.10% | 12.11% | 24.03% | 6.71% |
Effective Tax Rate | 45.71% | - | - | 8.95% | - |
Advertising Expenses | 1,173 | 868.01 | 817.01 | 995.38 | 194.38 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.